Highlights

The tumour-promoting activities of a famous protein

The tumour-promoting activities of a famous protein

Developing new cancer therapies and a more reliable test for prostate cancer are just some of the potential outcomes of Mauri...

read the full story

Newly funded research highlights MWC collaborations

Newly funded research highlights MWC collaborations

A five-year research programme aims to develop nontoxic vaccine technologies to complement existing cancer immunotherapies.

read the full story

Cancer drug advances to phase II clinical trials

Cancer drug advances to phase II clinical trials

A New Zealand cancer drug developed by two Maurice Wilkins Centre investigators has reached the second phase of clinical tria...

read the full story

New chemistry transforms cancer vaccine (2013)

New chemistry transforms cancer vaccine (2013)

A new kind of chemistry that dramatically simplifies the manufacture of cancer vaccines was created this year by Honours stud...

read the full story

New therapies - from a new generation (2013)

New therapies - from a new generation (2013)

Nurturing the next generation of scientists is an important part of the Maurice Wilkins Centre’s work – and senior students c...

read the full story

A licence to manufacture medicines (2012)

A licence to manufacture medicines (2012)

A licence to manufacture medicines has been granted to a University of Auckland facility that will produce the active ingredi...

read the full story

New Zealand patients trial local cancer drug (2012)

New Zealand patients trial local cancer drug (2012)

Cancer patients in Auckland, Waikato and the United States are participating in the first clinical trial of an exciting new d...

read the full story

The future of vaccines (2012)

The future of vaccines (2012)

Maurice Wilkins Centre investigator Professor Sarah Hook from the University of Otago is developing new vaccine formulations ...

read the full story

New drug targets treatment-resistant cancer (2011)

New drug targets treatment-resistant cancer (2011)

A new drug targeting an important group of cancer cells attracted international funding in 2011 and will soon enter clinical ...

read the full story